133 related articles for article (PubMed ID: 22515400)
1. The risk of AIDS-defining events is decreasing over time in the German HIV-1 Seroconverter Cohort.
Altmann M; An der Heiden M; Scheufele R; Hartmann K; Houareau C; Bartmeyer B; Hamouda O;
BMC Infect Dis; 2012 Apr; 12():94. PubMed ID: 22515400
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999.
del Amo J; del Romero J; Barrasa A; Pérez-Hoyos S; Rodríguez C; Díez M; García S; Soriano V; Castilla J;
Sex Transm Infect; 2002 Aug; 78(4):255-60. PubMed ID: 12181462
[TBL] [Abstract][Full Text] [Related]
3. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.
Detels R; Muñoz A; McFarlane G; Kingsley LA; Margolick JB; Giorgi J; Schrager LK; Phair JP
JAMA; 1998 Nov; 280(17):1497-503. PubMed ID: 9809730
[TBL] [Abstract][Full Text] [Related]
5. Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters.
Cain LE; Cole SR; Chmiel JS; Margolick JB; Rinaldo CR; Detels R
Am J Epidemiol; 2006 Feb; 163(4):310-5. PubMed ID: 16371516
[TBL] [Abstract][Full Text] [Related]
6. Determinants of survival following HIV-1 seroconversion after the introduction of HAART.
Porter K; Babiker A; Bhaskaran K; Darbyshire J; Pezzotti P; Porter K; Walker AS;
Lancet; 2003 Oct; 362(9392):1267-74. PubMed ID: 14575971
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category.
Pérez-Hoyos S; del Amo J; Muga R; del Romero J; García de Olalla P; Guerrero R; Hernàndez-Aguado I;
AIDS; 2003 Feb; 17(3):353-9. PubMed ID: 12556689
[TBL] [Abstract][Full Text] [Related]
8. [Socio-demographic factors associated with the progression of HIV infection and the impact of HAART in a seroconverter cohort in Madrid (1986-2009)].
Monge S; Del Romero J; Rodríguez C; de Mendoza C; de Górgolas M; Cosín J; Dronda F; Pérez-Cecilia E; Peña JM; Santos I; Rubio R; Del Amo J;
Enferm Infecc Microbiol Clin; 2012 Mar; 30(3):117-23. PubMed ID: 22014512
[TBL] [Abstract][Full Text] [Related]
9. Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters.
Shiels MS; Cole SR; Wegner S; Armenian H; Chmiel JS; Ganesan A; Marconi VC; Martinez-Maza O; Martinson J; Weintrob A; Jacobson LP; Crum-Cianflone NF
J Acquir Immune Defic Syndr; 2008 Aug; 48(4):485-90. PubMed ID: 18614916
[TBL] [Abstract][Full Text] [Related]
10. Impact of highly active antiretroviral therapy (HAART) on AIDS and death in a cohort of vertically HIV type 1-infected children: 1980-2006.
Palladino C; Bellón JM; Jarrín I; Gurbindo MD; De José MI; Ramos JT; González-Iome MI; Mellado MJ; Beceiro J; Del Amo J; Muñoz-Fernández MA
AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1091-7. PubMed ID: 19895191
[TBL] [Abstract][Full Text] [Related]
11. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women.
Jarrin I; Geskus R; Bhaskaran K; Prins M; Perez-Hoyos S; Muga R; Hernández-Aguado I; Meyer L; Porter K; del Amo J;
Am J Epidemiol; 2008 Sep; 168(5):532-40. PubMed ID: 18663213
[TBL] [Abstract][Full Text] [Related]
12. [AIDS incubation period in Spain before highly active antiretroviral therapy].
Med Clin (Barc); 2000 Nov; 115(18):681-6. PubMed ID: 11141426
[TBL] [Abstract][Full Text] [Related]
13. Changing trends in clinical AIDS presentations and survival among HIV-1-infected women.
Charurat M; Blattner W; Hershow R; Buck A; Zorrilla CD; Watts DH; Paul M; Landesman S; Adeniyi-Jones S; Tuomala R;
J Womens Health (Larchmt); 2004; 13(6):719-30. PubMed ID: 15333287
[TBL] [Abstract][Full Text] [Related]
14. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe.
Lancet; 2000 Apr; 355(9210):1131-7. PubMed ID: 10791375
[TBL] [Abstract][Full Text] [Related]
15. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
Ives NJ; Gazzard BG; Easterbrook PJ
J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study.
Dorrucci M; Pezzotti P; Phillips AN; Alliegro MB; Rezza G
AIDS; 1997 Mar; 11(4):461-7. PubMed ID: 9084793
[TBL] [Abstract][Full Text] [Related]
17. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.
García de la Hera M; Ferreros I; del Amo J; García de Olalla P; Pérez Hoyos S; Muga R; del Romero J; Guerrero R; Hernández-Aguado I;
J Epidemiol Community Health; 2004 Nov; 58(11):944-50. PubMed ID: 15483312
[TBL] [Abstract][Full Text] [Related]
18. HIV seroincidence and correlates of seroconversion in a cohort of male factory workers in Harare, Zimbabwe.
Mbizvo MT; Machekano R; McFarland W; Ray S; Bassett M; Latif A; Katzenstein D
AIDS; 1996 Jul; 10(8):895-901. PubMed ID: 8828747
[TBL] [Abstract][Full Text] [Related]
19. Influence of highly active anti-retroviral therapy (HAART) on the natural history of extra-pulmonary tuberculosis in HIV patients.
García de Olalla P; Martínez-González MA; Caylà JA; Jansà JM; Iglesias B; Guerrero R; Marco A; Gatell JM; Ocaña I;
Int J Tuberc Lung Dis; 2002 Dec; 6(12):1051-7. PubMed ID: 12546112
[TBL] [Abstract][Full Text] [Related]
20. Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. European Seroconverter Study and the Tricontinental Seroconverter Study.
Prins M; Veugelers PJ
AIDS; 1997 Apr; 11(5):621-31. PubMed ID: 9108944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
